Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
Anna Małgorzata CzarneckaPaweł TeteryczAnna Mariuk-JaremaIwona LugowskaPawel RogalaMonika Dudzisz-SledzTomasz SwitajPiotr RutkowskiPublished in: Targeted oncology (2020)
In BRAF mutated patients with normal LDH, first-line immunotherapy seems a more effective approach. We have demonstrated that although BRAF mutation is a negative prognostic factor in stage IV melanoma, the use of two different systemic treatment modalities allows achievement of comparable survival in BRAF mutated and BRAF wild-type patients.